- Home
- CEPU vs RARE Comparison
CEPU vs RARE Comparison
Compare CEPU & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEPU | RARE |
|---|---|---|
| Founded | 1989 | 2010 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2017 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CEPU | RARE |
|---|---|---|
| Price | $10.22 | $16.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 21 |
| Target Price | ★ $27.28 | $25.35 |
| AVG Volume (30 Days) | 298.0K | ★ 3.5M |
| Earning Date | 11-12-2026 | 11-03-2026 |
| Dividend Yield | ★ 9.02% | N/A |
| EPS Growth | N/A | ★ 7.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $673,000,000.00 |
| Revenue This Year | $62.50 | $12.70 |
| Revenue Next Year | $2.24 | $29.06 |
| P/E Ratio | $12.24 | ★ N/A |
| Revenue Growth | N/A | ★ 20.13 |
| 52 Week Low | $9.61 | $12.73 |
| 52 Week High | $18.50 | $39.89 |
Technical Indicators
Market Signals| Indicator | CEPU | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 30.81 | 51.28 |
| Support Level | N/A | $14.11 |
| Resistance Level | $15.65 | $26.27 |
| Average True Range (ATR) | 0.46 | 0.89 |
| MACD | -0.12 | 0.07 |
| Stochastic Oscillator | 21.63 | 47.25 |
Price Performance
Historical ComparisonAbout CEPU Central Puerto S.A. (each represents ten)
Central Puerto SA is a power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity. The company derives maximum revenue from Electric Power Generation from conventional sources segment.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.